Big Data portal for Alzheimer’s drug discovery launched

The National Institutes of Health (NIH) and its partners have launched a new Big Data portal, the AMP-AD Knowledge Portal, to speed Alzheimer’s drug discovery. “We are determined to reduce the cost and time it takes to discover viable therapeutic targets and bring new diagnostics and effective therapies to people with Alzheimer’s. That demands a new way of doing business,” said NIH Director Francis S. Collins, M.D., Ph.D. The AMP-AD Knowledge Portal enables the wider research community to share and analyze large and complex biomedical datasets. The goal is for researchers to ramp up the development of predictive models of Alzheimer’s disease and find novel targets that drive the clinical signs and symptoms of the disease. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) initiative, a partnership among government, industry, and nonprofit organizations including NIH, the U.S. Food and Drug Administration, industry and academic scientists from a variety of disciplines. The Portal was developed by Sage Bionetworks, a Seattle-based non-profit organization promoting open science. Share this information on social media with the following message: AMP-AD Big Data portal for #Alzheimers drug discovery launched by @NIH @Sagebio & partners. http://1.usa.gov/1wJrMoi STAY CONNECTED